Historically, first-line therapies for advanced STS have not significantly improved OS compared to treatment with doxorubicin1,6
References: 1. Ravi V, Patel S, Benjamin RS. Chemotherapy for soft-tissue sarcomas. Oncology. Cancer Network. http://www.cancernetwork.com/oncology-journal/chemotherapy-soft-tissue-sarcomas. Published January 15, 2015. Accessed October 17, 2016. 2. Italiano A, Mathoulin-Pelissier S, Le Cesne A, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049-1054. 3. Quesada J, Amato R. The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma. 2012:1-16. doi: 10.1155/2012/849456. 4. American Cancer Society. Sarcoma: Adult soft tissue cancer. http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-soft-tissue-sarcoma. Atlanta, GA: American Cancer Society. Updated February 2016. Accessed October 17, 2016. 5. SEER Cancer Statistics Fast Stats. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/faststats/selections.php?run=runit&output=2&data=4&statistic=6&year=201607&race=1&sex=1&age=1&series=cancer&cancer=1%3b51#Output. Accessed October 11, 2016. 6. Judson I, Verweij J, Gelderblom H, et al; for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet. 2014;15:415-423. 7. Fletcher CDM, Sundaram M, Rydholm A, Coindre JM, Singer S. Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:12-18.
You are now leaving the www.LARTRUVO.com website.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016